Pneumoconiosis future or investigational therapies

Jump to navigation Jump to search

Pneumoconiosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pneumoconiosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pneumoconiosis future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pneumoconiosis future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pneumoconiosis future or investigational therapies

CDC on Pneumoconiosis future or investigational therapies

Pneumoconiosis future or investigational therapies in the news

Blogs on Pneumoconiosis future or investigational therapies

Directions to Hospitals Treating Pneumoconiosis

Risk calculators and risk factors for Pneumoconiosis future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dushka Riaz, MD

Overview

Future or Investigational Therapies

Future therapies are being experimented on including inhibiting cytokines and the use of antioxidants. Investigational therapy also includes administration of bone marrow-derived mononuclear cells. [1] [2] [3]

References

  1. Rimal B, Greenberg AK, Rom WN (2005). "Basic pathogenetic mechanisms in silicosis: current understanding". Curr Opin Pulm Med. 11 (2): 169–73. doi:10.1097/01.mcp.0000152998.11335.24. PMID 15699791.
  2. Maron-Gutierrez T, Castiglione RC, Xisto DG, Oliveira MG, Cruz FF, Peçanha R; et al. (2011). "Bone marrow-derived mononuclear cell therapy attenuates silica-induced lung fibrosis". Eur Respir J. 37 (5): 1217–25. doi:10.1183/09031936.00205009. PMID 20693250.
  3. Cavalli G, Fallanca F, Dinarello CA, Dagna L (2015). "Treating pulmonary silicosis by blocking interleukin 1". Am J Respir Crit Care Med. 191 (5): 596–8. doi:10.1164/rccm.201412-2150LE. PMID 25723826.

Template:WH Template:WS